Do analysts recommend NVNO or VVOS?

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,611.49%. Given Vivos Therapeutics' higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Vivos Therapeutics (VVOS) Competitors

$0.16 -0.01 (-7.41%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$0.16 0.00 (-2.81%)

As of 04:42 AM Eastern

Compare

VVOS vs. MBAI, NDRA, NVNO, SINT, and ICCM

Should you buy Vivos Therapeutics stock or one of its competitors? Vivos Therapeutics's main competitors and comparable companies include Check-Cap (MBAI), ENDRA Life Sciences (NDRA), enVVeno Medical (NVNO), Sintx Technologies (SINT), and IceCure Medical (ICCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Vivos Therapeutics compare to Check-Cap?

Vivos Therapeutics (NASDAQ:VVOS) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Check-Cap has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. Check-Cap's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Check-Cap	N/A	N/A	N/A

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vivos Therapeutics has a beta of 6.04, indicating that its stock price is 504% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 1,611.49%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has lower revenue, but higher earnings than Vivos Therapeutics. Check-Cap is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

In the previous week, Check-Cap had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for Check-Cap and 2 mentions for Vivos Therapeutics. Check-Cap's average media sentiment score of 0.62 beat Vivos Therapeutics' score of 0.29 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Check-Cap	Positive

Summary

Vivos Therapeutics beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to ENDRA Life Sciences?

Vivos Therapeutics (NASDAQ:VVOS) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Vivos Therapeutics had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.89 beat Vivos Therapeutics' score of 0.29 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
ENDRA Life Sciences	Very Positive

Vivos Therapeutics has a beta of 6.04, suggesting that its share price is 504% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

ENDRA Life Sciences has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. ENDRA Life Sciences' return on equity of -246.34% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 1,611.49%. ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 346.43%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ENDRA Life Sciences has lower revenue, but higher earnings than Vivos Therapeutics. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

Summary

Vivos Therapeutics beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

enVVeno Medical has higher earnings, but lower revenue than Vivos Therapeutics. enVVeno Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,611.49%. Given Vivos Therapeutics' higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

enVVeno Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. enVVeno Medical's return on equity of -62.28% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

enVVeno Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.04, indicating that its stock price is 504% more volatile than the broader market.

In the previous week, enVVeno Medical had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for enVVeno Medical and 2 mentions for Vivos Therapeutics. enVVeno Medical's average media sentiment score of 0.38 beat Vivos Therapeutics' score of 0.29 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Overall Sentiment
enVVeno Medical	Neutral
Vivos Therapeutics	Neutral

Summary

enVVeno Medical beats Vivos Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Sintx Technologies?

Vivos Therapeutics (NASDAQ:VVOS) and Sintx Technologies (NASDAQ:SINT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.62 beat Vivos Therapeutics' score of 0.29 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Sintx Technologies	Positive

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 1,611.49%. Sintx Technologies has a consensus target price of $9.33, suggesting a potential upside of 449.02%. Given Vivos Therapeutics' higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Sintx Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sintx Technologies has lower revenue, but higher earnings than Vivos Therapeutics. Sintx Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A
Sintx Technologies	$1.02M	7.20	-$10.36M	-$4.91	N/A

Vivos Therapeutics has a net margin of -122.00% compared to Sintx Technologies' net margin of -848.20%. Sintx Technologies' return on equity of -354.44% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Sintx Technologies	-848.20%	-354.44%	-115.37%

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 4.1% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vivos Therapeutics and Sintx Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Vivos Therapeutics compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.04, meaning that its share price is 504% more volatile than the broader market.

Vivos Therapeutics has a net margin of -122.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

IceCure Medical has higher earnings, but lower revenue than Vivos Therapeutics. IceCure Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	2.08	-$15.06M	-$8.52	N/A
Vivos Therapeutics	$17.44M	0.13	-$21.17M	-$1.90	N/A

In the previous week, IceCure Medical had 3 more articles in the media than Vivos Therapeutics. MarketBeat recorded 5 mentions for IceCure Medical and 2 mentions for Vivos Therapeutics. IceCure Medical's average media sentiment score of 0.57 beat Vivos Therapeutics' score of 0.29 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Overall Sentiment
IceCure Medical	Positive
Vivos Therapeutics	Neutral

IceCure Medical currently has a consensus target price of $52.50, indicating a potential upside of 2,460.98%. Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,611.49%. Given IceCure Medical's higher probable upside, analysts plainly believe IceCure Medical is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

IceCure Medical and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.46M	$5.54B	$7.21B	$15.01B
Dividend Yield	N/A	1.79%	2.57%	12.21%
P/E Ratio	-0.09	25.08	272.90	25.31
Price / Sales	0.13	72.31	723.41	107.94
Price / Cash	N/A	32.78	77.71	51.48
Price / Book	-1.02	5.99	10.44	6.18
Net Income	-$21.17M	$150.13M	$3.49B	$357.96M
7 Day Performance	-3.88%	-1.18%	-0.75%	-0.56%
1 Month Performance	-52.34%	-3.80%	-0.38%	-3.62%
1 Year Performance	-95.19%	8.44%	18.95%	6.05%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	2.037 of 5 stars	$0.16 -7.4%	$2.80 +1,611.5%	-95.2%	$2.46M	$17.44M	N/A	160	Short Interest Increase Gap Down
MBAI Check-Cap	0.3941 of 5 stars	$6.40 +0.6%	N/A	N/A	$8.83M	N/A	N/A	80
NDRA ENDRA Life Sciences	2.6659 of 5 stars	$5.78 -2.2%	$25.00 +332.7%	+15.0%	$8.58M	N/A	N/A	20	Positive News Gap Up
NVNO enVVeno Medical	2.1094 of 5 stars	$11.32 -1.5%	N/A	-70.6%	$7.81M	N/A	N/A	30
SINT Sintx Technologies	1.8607 of 5 stars	$1.71 -1.7%	$9.33 +445.5%	-60.7%	$7.39M	$1.09M	N/A	40	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MBAI, NDRA, NVNO, SINT, and ICCM

How does Vivos Therapeutics compare to Check-Cap?

Summary

How does Vivos Therapeutics compare to ENDRA Life Sciences?

Summary

How does Vivos Therapeutics compare to enVVeno Medical?

Summary

How does Vivos Therapeutics compare to Sintx Technologies?

Summary

How does Vivos Therapeutics compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MBAI, NDRA, NVNO, SINT, and ICCM

How does Vivos Therapeutics compare to Check-Cap?

Is VVOS or MBAI more profitable?

Do institutionals and insiders believe in VVOS or MBAI?

Which has more risk & volatility, VVOS or MBAI?

Do analysts recommend VVOS or MBAI?

Which has preferable valuation & earnings, VVOS or MBAI?

Does the media prefer VVOS or MBAI?

Summary

How does Vivos Therapeutics compare to ENDRA Life Sciences?

Does the media refer more to VVOS or NDRA?

Which has more volatility & risk, VVOS or NDRA?

Is VVOS or NDRA more profitable?

Do analysts rate VVOS or NDRA?

Do institutionals and insiders believe in VVOS or NDRA?

Which has stronger valuation & earnings, VVOS or NDRA?

Summary

How does Vivos Therapeutics compare to enVVeno Medical?

Which has better valuation & earnings, NVNO or VVOS?

Do analysts recommend NVNO or VVOS?

Is NVNO or VVOS more profitable?

Do institutionals and insiders have more ownership in NVNO or VVOS?

Which has more volatility & risk, NVNO or VVOS?

Does the media refer more to NVNO or VVOS?

Summary

How does Vivos Therapeutics compare to Sintx Technologies?

Does the media refer more to VVOS or SINT?

Do analysts prefer VVOS or SINT?

Which has preferable valuation & earnings, VVOS or SINT?

Is VVOS or SINT more profitable?

Do insiders and institutionals have more ownership in VVOS or SINT?

Summary

How does Vivos Therapeutics compare to IceCure Medical?

Which has more volatility and risk, ICCM or VVOS?

Is ICCM or VVOS more profitable?

Which has stronger valuation & earnings, ICCM or VVOS?

Does the media favor ICCM or VVOS?

Do analysts recommend ICCM or VVOS?

Do institutionals & insiders believe in ICCM or VVOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools